GPs can now prescribe a £1 pill to help prevent chronic kidney disease, experts say

A low-cost pill that GPs can now prescribe offers a new tool to help prevent chronic kidney disease, health experts say, as the condition continues to affect millions of Britons and impose mounting costs on the NHS.

Chronic kidney disease (CKD), a progressive loss of kidney function often without symptoms until late stages, already affects more than 7.2 million people in the United Kingdom and is linked to roughly 45,000 deaths each year — more than fatalities from breast and prostate cancer combined. Because the disease can be symptomless until the kidneys are close to failing, at least 1 million people are believed to be living with CKD without knowing it.

Clinicians and health analysts have warned that CKD represents a ‘‘slow-moving tidal wave’’ for the health service, with diagnoses and demand for kidney replacement therapies set to rise. The number of people diagnosed is expected to increase by about 400,000 over the next decade. Dialysis, the life-sustaining but resource-intensive treatment for kidney failure, is already among the NHS’s largest expenditures and is forecast to cost about £13 billion a year by the end of the decade.

The pressure on transplant services is also expected to grow. The number of patients waiting for kidney transplants is forecast to triple by 2033, and nearly 1,000 people currently die each year while awaiting a donor kidney.

Public-health experts say the new prescribing option could help reduce the number of people who progress to advanced kidney failure, but they caution that early detection remains critical. CKD frequently causes no clear symptoms until significant damage has occurred, which limits opportunities for intervention. That combination of silent progression and an ageing population has driven concern among clinicians and planners.

Health officials and GP practices have been urged to prioritise case finding in at-risk groups, and to consider the pill alongside existing blood-pressure control, diabetes management and lifestyle measures that are known to protect kidney function. The pill, described by sources as costing about £1, is intended to be an additional preventive measure available to primary-care prescribers; details on eligibility, monitoring and expected population impact are being considered by clinical teams and local health boards.

The anticipated growth in CKD cases reflects wider demographic and clinical trends. An ageing population and rising prevalence of conditions associated with kidney damage have contributed to the increase in both diagnosed and undiagnosed disease, placing pressure on routine services, specialist nephrology care and renal replacement therapies.

Clinicians say that improving awareness among patients and healthcare professionals, expanding targeted testing for high-risk groups and ensuring access to effective preventive medicines will be important to slow the projected rise in dialysis and transplant demand. Health-system planners are evaluating the potential budgetary and service implications of wider use of the new pill alongside other prevention strategies.

While the new prescribing option has been welcomed as a potentially cost-effective addition to CKD prevention, experts stressed that it is not a replacement for early diagnosis, comprehensive risk-factor management or specialist care for people with advanced disease. Continued monitoring and evaluation will be necessary to determine how much the measure reduces progression to kidney failure and eases pressure on the NHS.